In an analysis of pooled data from 6 controlled trials evaluating pregabalin in patients with GAD, there was a significant reduction in depressive symptoms versus placebo, and these effects were apparent in patients with more prominent depressive symptoms at baseline.4 In a separate randomized controlled trial, adjunctive pregabalin in patients with GAD and suboptimal response to prior therapy was associated with significant improvements in anxiety symptoms versus placebo.5
References:
1. Davies A, Hendrich J, Van Minh AT, et al. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007; 28 (5): 220–228.
2. Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol 2016; 594 (19): 5369–5390.
3. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28 (5): 403–439.
4. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18 (6): 422–430.
5. Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012; 27 (3): 142–150.
6. Baldwin DS, Masdrakis V. Non-prescribed use of gabapentinoids: mechanisms, predisposing factors, associated hazards and clinical management. Eur Neuropsychopharmacol 2022; 63: 6–8.
7. Ashworth J, Bajpaia R, Muller S, et al. Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. Lancet Region Health – Europe 2023; 27: 1000579.
